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Abstract: Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor
lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation
therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT
on the detection rate of 68Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy
and 68Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score
matching was used to create two balanced groups of 62 subjects who either did or did not receive
ADT within six months before imaging. All 68Ga-PSMA ligand PET/CT were evaluated visually and
with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in
the group with ADT (88.7% vs. 72.6%, p = 0.02) and improved with increasing PSA-levels in both
groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (p < 0.01)
and PSMA-derived tumor volume (p < 0.01) were significantly higher than in those without ADT.
More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT
suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to
high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA
ligand PET/CT cannot be recommended.
Keywords: 68Ga-PSMA ligand PET/CT; androgen deprivation therapy; detection rate; recurrent
prostate cancer
1. Introduction
Biochemical recurrence (BCR), defined by an increase of the prostate-specific antigen (PSA), occurs
in up to 50% of the patients within five years after radical prostatectomy (RP) [1]. Treatment decisions
following BCR must balance the risk of metastatic disease to potential treatment side effects (e.g., on
patients’ quality of life) while avoiding overtreatment at low risk of clinical progression. Different
treatment modalities for managing these patients are available, but their application and timing
remain controversial due to limited evidence [2]. Androgen deprivation therapy (ADT) is the standard
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treatment of locally advanced (in combination with radiation therapy) and metastatic disease [3,4].
In the BCR-setting, ADT should be reserved for patients at highest risk of disease progression, mainly
defined by a short PSA doubling time (<6–12 months) [5]. However, BCR, continuously increasing
PSA levels in patients with and without ADT, and a PSA relapse over time after an initial treatment
effect in patients receiving ADT require effective staging procedures for recurrent prostate cancer (PC).
Within the past years, molecular imaging probes targeting the prostate-specific membrane antigen
(PSMA) have established for PET/CT imaging in the primary and secondary staging of PC [5,6]. PSMA
is a membrane protein, which shows increased expression levels in PC cells [7]. Moreover, 68Ga- or
18F-labeled PSMA ligands enable the localization of tumor manifestations and thus help to differentiate
between local, regional, and systemic disease in recurrent PC, which is crucial for subsequent treatment
decisions. A meta-analysis of retrospective studies and a recent prospective multicenter trial on
68Ga-PSMA ligand PET/CT revealed that detection rate in recurrent PC depends on the PSA-value, and
rises from 38% (PSA-levels < 0.5 ng/mL) up to 97% (PSA-levels ≥ 5 ng/mL) [8,9]. However, the influence
of androgen deprivation therapy (ADT) on the detection efficacy of PSMA ligand PET/CT is unclear
since incongruent findings have been reported from different centers [10,11]. An association of a positive
68Ga-PSMA ligand PET/CT with ADT was observed, though the significance in multivariate logistic
regression analysis depended on the inclusion and scaling of other variables [12]. Direct comparisons of
the detection rate in patients with vs. patients without ADT are limited due to unmatched PSA-values
between groups [13,14]. Furthermore, the actual biological effect of androgen receptor inhibition on
PSMA ligand uptake is controversial. Whereas short-term ADT seems to increase the uptake at least
in some PC lesions [15–18], the treatment effect of long-term ADT might be accompanied by a lower
PSMA ligand uptake and thus, a reduced visibility of tumor lesions [19].
The aim of this study was therefore to directly compare the detection rate of 68Ga-PSMA ligand
PET/CT in two balanced patient groups with and without ADT. We additionally estimated the tumor
burden and PSMA expression by collecting 68Ga-PSMA ligand PET-derived quantitative parameters to
disentangle whether deviant detection rates between groups is related to a higher visibility of tumor
lesions or a different disease stage. Finally, this study aims to provide a recommendation for clinicians,
who consider the withdrawal of ADT before PSMA-ligand PET/CT imaging.
2. Experimental Section
2.1. Study Design
This is a retrospective case-control study of patients with recurrent PC who underwent 68Ga-PSMA
ligand PET/CT for diagnostic purposes between April 2014 and September 2018 at the Department of
Nuclear Medicine, University Hospital Würzburg, Germany.
2.2. Patients
We extracted 572 patients with PSA relapse after initial therapy with curative intent, who
performed 68Ga-PSMA ligand PET/CT from the institution’s database. Only patients who fulfilled the
following criteria were included in the study: initial treatment with radical prostatectomy, a PSA-value
between 0.2 and 20 ng/mL (not older than 3 months prior to imaging) and an available Gleason
score from prostatectomy specimens. Patients with prior chemotherapy or new-generation androgen
receptor inhibitor were excluded (for patient flow see Supplementary Figure S1).
2.3. Grouping
The patients (n = 399) were split into two groups, one containing patients, who received ADT
during/within six months prior imaging (n = 65) [13], the second containing subjects without ADT
(n = 334). The latter served to create a control group of patients without ADT, that was balanced to the
group of patients with ADT. We used propensity score matching (caliper set at 0.05) for the assignment
into the control group with following covariates: PSA-levels (ng/mL) converted to a natural logarithmic
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scale (log PSA), Gleason score, adjuvant or salvage radiotherapy and injected activity divided by body
weight (MB q/kg).
2.4. Preparation of 68Ga-PSMA ligand
68Ga-PSMA imaging and therapy (I&T) labelling was performed on a fully automated GRP
module (Scintomics, Fürstenfeldbruck, Germany) in combination with cassettes produced by ABX (ABX,
Radeberg, Germany). A 68Ge/68Ga-generator (GalliaPharm®, Eckert & Ziegler AG, Berlin, Germany)
was eluted with 0.1 N HCl, the eluate trapped on a cation exchange cartridge, and eluted with 5 N NaCl.
Labelling of 20 µg PSMA I&T (Scintomics, Fürstenfeldbruck, Germany) was performed by heating the
eluate for 6 min at 125 ◦C in the presence of HEPES-buffer. Then the reaction mixture was purified on a
SepPak C18-cartridge, eluted with ethanol/water 50/50 and diluted with phosphate buffer solution to a
total volume of 15 mL. A sample was taken for determination of radiochemical purity, radionuclide
purity, ethanol content, pH, sterility, and endotoxins.
2.5. Imaging
All patients underwent 68Ga-PSMA I&T imaging on an integrated PET/CT scanner (Siemens
Biograph mCT 64, Siemens Healthineers, Knoxville, TN, USA). The protocol included a distribution
period of 60 min after injection of 68Ga-PSMA I&T. Whole-body PET was acquired in 3D-mode from
the proximal thighs up to the upper jaw by using 2 min scan time per bed position. Subsequently,
all patients underwent diagnostic CT scans with contrast enhancement and following parameters:
180 mAs (quality reference for dose modulation), 120 kV, 512 × 512 matrix, 5 mm slice thickness,
30 mm/s increment, 0.5 s rotation time, and a pitch index of 1.4. Three iterations, 24 subsets, and
post-reconstruction Gaussian filtering of 2.0 mm full-width at half-maximum were used for iterative
PET data reconstruction with attenuation correction (HD. PET, Siemens Esoft, Siemens Healthineers,
Erlangen, Germany).
2.6. Image Analysis
All images were interpreted by one board-certified nuclear medicine physician (J.B.) and one
board-certified radiologist (A.D.) in consensus reading on a syngo.via workstation (Siemens Healthineers,
Erlangen, Germany). Then, 68Ga-PSMA I&T PET and CT images were rated for lesions suggestive
for tumor recurrence and number of lesions for local recurrence, lymph node metastases (separated
into pelvic, retroperitoneal, and supradiaphragmatic location), bone metastases and organ metastases
were noted. PET images were assessed regarding focal uptake of 68Ga-PSMA I&T higher than the
surrounding background and not related to a physiologic pattern [13]. In CT, any lymph node with a
short axis diameter > 5 mm, pathologic pelvic lesions, and sclerotic bone lesions without association
to degenerative changes were rated suggestive for malignancy. In all suspected pathological lesions,
following PET-derived parameters were measured: highest maximum standardized uptake values
(SUVmax), total lesion PSMA (TL-PSMA), and PSMA total volume (PSMA-TV) [20,21]. Subsequently,
we identified the highest SUVmax and summarized whole-body TL-PSMA and PSMA-TV (wbTL-PSMA,
wbPSMA-TV) for each patient.
2.7. Statistical Analysis
The balancing of covariates after propensity score matching was evaluated by using students t and
Chi-square test. The latter was also used to compare detection rate between groups. Binary logistic
regression analysis was performed with the detection rate as dependent variable and the factors ADT
(yes/no), radiotherapy (yes/no), Gleason score (5–7/8–10), log PSA, and injected radioactivity per kg body
weight. Numeric and volumetric imaging-derived parameters were compared using Mann–Whitney U
test. The association between PSA-level and imaging parameters was assessed with Spearman’s rank
correlation coefficient (σ). Our main hypothesis was that the detection rate differs between groups,
whereas the evaluation of imaging-derived parameters was considered exploratory. Therefore, we
defined a p value < 0.05 as significant for all analysis. Quantitative values are displayed as mean ±
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standard deviation or as median and range, as appropriate. Data were analyzed with SPSS statistics
(Version 25.0, IBM corp., Armonk, NY, USA).
2.8. Ethics Approval and Patient Consent
The retrospective analysis was approved by the local institutional review board of the
Julius-Maximilian University Würzburg (AZ: 20200210-02; approval date: 27 February 2020). 68Ga-PSMA
I&T PET/CT scans were performed as part of the clinical work-up and were in accordance with the
principles of the Declaration of Helsinki and its later amendments. All patients gave written informed
consent to the diagnostic procedure.
3. Results
3.1. Patient Groups
Before propensity score matching, the patients with ADT showed a significantly higher PSA-value,
had a higher Gleason score, and were more often treated with radiation therapy than patients without
ADT; the mean injected radioactivity did not differ between groups. Propensity score matching balanced
all four covariates between groups by yielding a match for 62 of 65 patients with ADT. The remaining
three patients were excluded. The covariates of both groups before and after matching are listed in
Table 1, the demographic and clinical characteristics of the final case and control groups are shown in
Table 2. By clinical definition [5] and considering PET/CT findings, 42 patients of the final ADT group had
a hormone-sensitive PC (HSPC), whereas 20 patients had a castration-resistant PC (CRPC) at imaging.
Table 1. Patient groups and covariates before and after Propensity score matching.
All Patients Matched Groups
ADT No ADT p ADT No ADT p
Patients n 65 334 62 62
PSA level
ng/mL 2.1 (0.2–18.4) 0.8 (0.2–16.4) 2.0 (0.2–18.4) 2.2 (0.3–16.4)






8–10 33 97 31 28
Radiation therapy yes 40 111 <0.001 #
37 35
0.716 #
no 25 223 25 27
Injected activity MBq/kg 1.51 ± 0.32 1.52 ± 0.33 0.923 § 1.50 ± 0.32 1.51 ± 0.31 0.855 §
Abbreviations: ADT = androgen deprivation therapy, PSA = prostate-specific antigen; PSA levels are given for the
time (< three months) prior to PET/CT, Gleason scores derived from prostatectomy specimens; p values refer to §
students t and # chi-squared tests.
Table 2. Demographic and clinical characteristics of case and control groups.
ADT No ADT
Age at primary diagnosis (years) 62 (48–74) 64 (45–80)
Time between RP and PET/CT (months) 82 (1–239) 69 (1–240)








Abbreviations: ADT = androgen deprivation therapy, RP = radical prostatectomy; T and R classification refer to
pathological findings at prostatectomy; † available in 59 patients with and in 55 patients without ADT; ‡ available in
40 patients with and in 49 patients without ADT.
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3.2. Detection Rate
The localizations of tumor recurrence for both groups are shown in Table 3. Recurrence was
more often detected in the group with ADT than in the control group (88.7% vs. 72.6%, p = 0.02)
and was higher with increasing PSA-levels in both groups (ADT: 60.0% (PSA: 0.2 to < 0.5 ng/mL),
85.7% (0.5 to < 1.0 ng/mL), 92.9% (1.0 to < 2.0 ng/mL), 96.8% (2.0 to < 20.0 ng/mL); no ADT: 37.5%
(0.2 to < 0.5 ng/mL), 63.6%(0.5 to < 1.0 ng/mL), 88.9% (1.0 to < 2.0 ng/mL), 79.4% (2.0 to < 20.0 ng/mL)).
Due to the small sample sizes, we refrained from further statistical comparisons of the PSA-level
subgroups. Within the ADT group, rates of positive PET/CT findings were slightly higher for CRPC
as compared to HSPC (95.0% vs. 85.7%). Tumor detection rate tended to be lower in subjects with a
Gleason score of 5 to 7 as compared to those with a higher Gleason score (8–10) (ADT: 83.9% (Gleason
5–7), 93.5% (8–10); p = 0.23; no ADT: 67.6% (5–7), 78.6% (8–10); p = 0.34; both groups: 75.4% (5–7),
86.4% (8–10); p = 0.12). Logistic regression analysis over both groups revealed, that log PSA (p < 0.001)
and ADT (p = 0.02) were predictors of a positive PET/CT, whereas injected radioactivity per kg body
weight, prior radiation therapy, and Gleason score were not. For log PSA, the probability of a positive
68Ga-PSMA I&T PET/CT finding increased with an odds ratio of 2.5 (95% confidence interval: 1.4–4.5)
per unit, and for ADT, the odds ratio was 3.9 (95% confidence interval: 1.3–11.6) (Figure 1).
Table 3. Spreading of prostate cancer recurrence in 68Ga-PSMA I&T PET/CT.
Region ADT No ADT
LR only 4 (6.5%) 9 (14.5%)
LN metastases only 25 (40.3%) 20 (32.3%)
Bone metastases only 11 (17.7%) 5 (8.1%)
LR + LN metastases 4 (6.5%) 2 (3.2%)
LR + bone metastases 0 (0.0%) 2 (3.2%)
LN + bone metastases 7 (11.3%) 7 (11.3%)
LR + visceral metastases 1 (1.6%) 0 (0.0%)
LN + visceral metastases 1 (1.6%) 0 (0.0%)
LR + LN + bone metastases 1 (1.6%) 0 (0.0%)
LR + LN + visceral metastases 1 (1.6%) 0 (0.0%)
Total 55 (88.7%) 45 (72.6%)
Abbreviations: ADT = androgen deprivation therapy, LR = local recurrence, LN = lymph.
Biomedicines 2020, 8, x FOR PEER REVIEW 5 of 11 
The localizations of tumor recurrenc  for both groups are shown in Table 3. Recurrence was more 
often detected in the group with ADT than in the control group (88.7% vs. 72.6%, p = 0.02) and was 
higher with increasing PSA-levels in both groups (ADT: 60.0% (PSA: 0.2 to < 0.5 ng/mL), 85.7% (0.5 
to < 1.0 ng/mL), 92.9% (1.0 to < 2.0 ng/mL), 96.8% (2.0 to < 20.0 ng/mL); no ADT: 37.5% (0.2 to < 0.5 
ng/mL), 63.6%(0.5 to < 1.0 ng/mL), 88.9% (1.0 to < 2.0 ng/mL), 79.4% (2.0 to < 20.0 ng/mL)). Due to the 
small sample sizes, we refrained from further statistical comparisons of the PSA-level subgroups. 
Within the ADT group, rates of positive PET/CT findings were slightly higher for CRPC as compared to 
HSPC (95.0% vs. 85.7%). Tumor detection rate tended to be lower in subjects with a Gleason score of 5 to 
7 as compared to those with a higher Gleason score (8–10) (ADT: 83.9% (Gleason 5–7), 93.5% (8–10); p 
= 0.23; no ADT: 67.6% (5–7), 78.6% (8–10); p = 0.34; both groups: 75.4% (5–7), 86.4% (8–10); p = 0.12). 
Logistic regression analysis ove  b th gr ups revealed, that log PSA (p < 0.001) and ADT (  = 0.02) 
were predictors f a positive PET/CT, whereas injected radioactivity per kg b dy weight, pri r 
radiation therapy, and Gleason score were not. For log PSA, the probability of a positive 68Ga-PSMA 
I&T PET/CT finding increased with an odds ratio of 2.5 (95% confidence interval: 1.4–4.5) per unit, 
and for ADT, the odds ratio was 3.9 (95% confidence interval: 1.3–11.6) (Figure 1). 
Table 3. Spreading of prostate cancer recurrence in 68Ga-PSMA I&T PET/CT. 
Region ADT no ADT 
LR only 4 (6.5%) 9 (14.5%) 
LN metastases only  25 (40.3%) 20 (32.3%) 
Bone metastases only 11 (17.7%) 5 (8.1%) 
LR + LN metastases 4 (6.5%) 2 (3.2%) 
LR + bone metastases 0 (0.0%) 2 (3.2%) 
LN + bone metastases 7 (11.3%) 7 (11.3%) 
LR + visceral metastases 1 (1.6%) 0 (0.0%) 
LN + visceral metastases 1 (1.6%) 0 (0.0%) 
LR + LN + bone metastases 1 (1.6%) 0 (0.0%) 
LR + LN + visceral metastases 1 (1.6%) 0 (0.0%) 
Total 55 (88.7%) 45 (72.6%) 
Abbreviations: ADT = androgen deprivation therapy, LR = local recurrence, LN = lymph. 
 
Figure 1. Logistic regression analysis. Estimated mean probability for a positive 68Ga-PSMA ligand 
PET/CT finding with regards to PSA values and presence of androgen deprivation therapy (ADT). 
Figure 1. Logistic regression analysis. Estimated ean probability for a positive 68Ga-PSMA ligand
PET/CT finding with regards to PSA values and presence of androgen deprivation therapy (ADT).
Biomedicines 2020, 8, 511 6 of 11
3.3. Quantitative Parameters
All examined 68Ga-PSMA I&T PET/CT derived parameters, i.e., number of suspicious lesions,
highest SUVmax per patient, wbTL-PSMA and wbPSMA-TV were significantly higher in the group with
ADT than in the group without ADT (Table 4). In patients with ADT, correlations with PSA-levels were
significant, though low (σ < 0.40) between PSA-values and SUVmax, wbTL-PSMA, and wbPSMA-TV.
The coefficient was slightly higher for wbTL-PSMA and wbPSMA-TV (σ = 0.52 and 0.51, respectively)
in the group without ADT, where also number of lesions correlated with PSA-levels (σ = 0.50). Since
these comparisons and correlations were substantially influenced by the number of negative cases, we
excluded these patients and repeated the analysis. Thereafter, only wbTL-PSMA and wbPSMA-TV
differed between groups and correlations between PSA levels and number of lesions (σ = 0.56),
wbTL-PSMA (σ = 0.60), and wbPSMA-TV (σ = 0.58) were only present in patients without antiandrogen
treatment (Table 4, Figure 2 and Supplementary Figure S2).
Table 4. Group comparison and correlational analysis of quantitative parameters in patients with and
without ADT.
Group Comparison Correlation with PSA-Level
ADT No ADT p * ADT p ◦ No ADT p ◦
All patients
n = 124
Number of lesions 2.5 (0–59) 1.0 (0–33) <0.01 0.24 0.06 0.50 <0.001
SUVmax 14.4 (0.0–181.1) 10.1 (0.0–107.1) 0.02 0.32 0.01 0.39 <0.01
wbTL-PSMA 31.5 (0.0–1489.7) 5.4 (0.0–481.2) <0.001 0.37 <0.01 0.52 <0.001




Number of lesions 3.0 (1–59) 2.0 (1–33) 0.15 0.07 0.60 0.56 <0.001
SUVmax 17.3 (5.1–181.1) 13.9 (4.4–107.1) 0.27 0.18 0.18 0.32 0.03
wbTL-PSMA 39.5 (2.8–1489.7) 12.8 (1.3–481.2) <0.01 0.24 0.08 0.60 <0.001
wbPSMA-TV 4.9 (0.2–268.1) 1.6 (0.1–41.0) <0.01 0.26 0.05 0.58 <0.001
Abbreviations: ADT = androgen deprivation therapy, PSA = prostate-specific antigen, SUVmax = maximum
standardized uptake value, wbTL-PSMA = whole-body total lesion PSMA, wbPSMA-TV = whole-body PSMA total
volume, p values refer to * Mann-Whitney U test and ◦ Spearman’s σ.Biomedicines 2020, 8, x FOR PEER REVIE  8 of 11 
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Figure 2. Plots with number of suspicious lesions over blood levels for prostate-specific antigen (PSA).
Displayed are the results of 68Ga-PSMA I&T PET/CT derived parameters of 55 patients with and
45 patients without androgen deprivation therapy (ADT), and pathological imaging findings. The upper
panel shows whole-body total lesion PSMA (wbTL-PSMA), the lower panel indicates the highest
maximum standardized uptake value (SUVmax) for each patient. Nine patients with ADT had a PSA
value below 2.0 ng/mL, but≥ 5 suspicious lesions, whereas this applied for only one patient without ADT.
4. Discussion
This study was designed to directly compare the detection rate of 68Ga-PSMA ligand PET/CT in
patients with recurrent PC, and with and without ADT, respectively. There are two main findings: first,
the detection rate is higher in patients receiving ADT than in patients, who have comparable PSA-levels
but do not undergo ADT. Second, the deviant detection rate is more likely related to the advanced
disease stage of patients with therapy, than to a treatment induced effect on PSMA-expression.
The precise detection and localization of tumor recurrence is crucial for subsequent management
in patients with rising PSA-levels after initial, curative treatment with RP. This comparison of patients
with and without ADT revealed an overall higher detection rate in patients with ADT, which was also
present in each subgroup according to the respective PSA-level. This leads to a higher mean probability
for a pathological finding in 68Ga-PSMA ligand PET/CT in patients receiving antiandrogen treatment
(Figure 1). This is in line with prior studies on PSMA ligand PET/CT gathering evidence for a higher
detection rate in patients with ADT [10,12–14]. However, this is the first study comparing groups, which
were balanced for relevant factors, such as PSA-levels, Gleason score and prior radiation treatment.
The detection rate of patients without treatment (72.6%) lies within the range (69.9%–76.7%) of
prior studies using the same radioligand, 68Ga-PSMA I&T, though these rates refer to cohorts also
containing patients with ADT [22,23]. As expected, we observed a rate for 68Ga-PSMA I&T PET/CT
below the detection efficacy in studies using other PSMA ligands such as 68Ga-PSMA-HBED-CC
(87.1%) or 18F-PSMA-1007 (78.0%) [13,14]. Although not balanced for PSA levels, these studies likewise
reported a higher detection rate in patients with ADT (95.7% and 91.7%, respectively). This suggests
that our finding is not limited to 68Ga-PSMA I&T and can be transferred to other radioligands targeting
PSMA expression. As previously reported, tumor recurrence was localized more often in patients with
a Gleason score≥ 8 than in patients with a Gleason≤ 7, albeit not reaching statistical significance [10–14].
This was also true for each group separately, indicating the lack of an interaction between Gleason
score and ADT, which influences the detection rate.
There are two potential explanations for the higher detection rate in patients with ADT: a higher
PSMA-expression induced by ADT in tumor cells and thus, a higher visibility of tumor lesions, or
higher tumor burden related to an advanced disease stage of patients with ADT. Whereas the duration
of ADT was neither associated with a positive or negative PET finding nor with higher wbTL-PSMA
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and wbPSMA-TV in the ADT group, we observed higher wbTL-PSMA and wbPSMA-TV and, albeit
not significantly, more patients had visceral and bone metastases within the ADT group than in the
group without treatment. Furthermore, both groups showed remarkably wide and predominantly
overlapping ranges of SUVmax. As depicted in Figure 2, high SUVmax values may occur in both groups
in patients with high and low PSA-values, irrespective of the number of lesions. This suggests that the
uptake is not primarily related to antihormonal treatment, but rather influenced by other factors such as
the tumor cell proliferation of a specific lesion. During antihormonal treatment, PC typically develops
androgen-resistance over time. Therefore, patients with CRPC have biologically different tumor lesions
than HSPC patients within the ADT and the control group [24]. Subgroup evaluations showed a
slightly higher detection rate and throughout higher quantitative imaging parameters in CRPC than
HSPC patients and a continuum from CRPC over HSPC to PC without ADT (see Supplementary Table
S1). However, a statistical comparison was not performed since PSA levels were unbalanced between
groups, and biochemical and radiological surveillance (e.g., frequency of PSA level evaluation, baseline
imaging) was not standardized in this retrospective cohort, potentially concealing a higher fraction of
CRPC patients. This also precludes any conclusion on whether the castration state influences PSMA
uptake, for which inconclusive findings have been presented so far [25,26]. Summarizing, a higher
tumor burden (and/or more tumor lesions) and not a direct effect on PSMA-expression are likely the
cause of better visibility and lead to a higher detection rate in patients with ADT.
These considerations refer to the rationale for antihormonal treatment. According to current
guidelines [5], ADT can be considered in BCR in case of a short PSA doubling time < 6–12 months, at
relapse, symptomatic progress, or distant metastasis. Due to therapy assignment, patients with ADT
are highly likely to be in more advanced disease stages than patients without treatment. However,
current clinical practice of patient surveillance, equally relies in both groups on PSA monitoring [27,28].
Whereas decreasing or low PSA-levels justify a wait-and-watch strategy in asymptomatic patients,
increasing levels provoke action and lead to further diagnostics. Our data confirm previously reported
correlations between PSA levels and tumor volume (i.e., wbTL-PSMA and wbPSMA-TV) in the group
without ADT [20,21]. Though, the lack of correlation between PSA levels and tumor volume in patients
with ADT challenges the reliability of PSA monitoring during antihormonal treatment. This is also
reflected by the high numbers of patients with a PSA level < 2 ng/ml but more than five suspicious
lesions (ADT: nine patients, no ADT: one patient; see Figure 2). We carefully reviewed the clinical
charts to control for whether these patients had a (treatment-related) neuroendocrine prostate cancer,
which would explain low PSA-values during advanced disease stages [29]. This was not the case in
any of the patients at RP. However, prostate adenocarcinoma with neuroendocrine differentiation not
only show low PSA-values, but also no or low PSMA expression [30], which conflicts with a moderate
SUVmax in most of these patients (Figure 2).
According to these findings, withdrawal of ADT cannot be recommended before PSMA ligand
PET/CT imaging, also not for patients with low PSA values. Considering the high detection rate in
patients with PSA-levels <2 ng/mL and the number of patients with low PSA value and advanced disease
stage, some patients might experience the risk of an accelerated tumor progression after treatment stop.
Regarding tumor surveillance during ADT, PSMA ligand PET/CT seems to be superior towards the
control of PSA blood levels in some cases. However, a broad clinical application is hampered due to the
imbalance of costs and benefits.
This study has some limitations. Due to the retrospective analysis, the duration of ADT, biochemical
surveillance and baseline imaging was not standardized so that included patients have a broad range
of treatment duration and have biologically heterogeneous tumor lesions (i.e., HSPC and CRPC).
Furthermore, we do not know the reason why treating physicians started ADT and which information
were available to them at the time of treatment initiation. We assumed treatment decisions according
to valid guidelines and paid attention, that selected covariates for the matching did not interfere with
these recommendations. Likewise, the PSMA-derived tumor volume as measure for tumor burden
might be affected by the actual PSMA expression. We controlled for this by comparing PSMA-derived
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tumor volume with morphologic, CT-based volume [31] and found strong correlations, which support
our findings and make a bias unlikely (see Supplementary Figure S3). However, this study does not
reveal the biological effect of short- and long-term ADT on PSMA expression, so that further studies
also involving preclinical models [32] are warranted.
5. Conclusions
PSMA ligand PET/CT has a higher detection rate in patients with PSA relapse undergoing ADT
than in subjects with comparable PSA-levels, who do not receive ADT. A better detection rate in
patients with ADT is more likely related to an advanced biological disease stage with higher tumor
burden. Considering the high detection rate in patients with PSA-levels < 2 ng/mL, the withdrawal of
ADT before PSMA ligand PET/CT cannot be recommended.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-9059/8/11/511/s1.,
Figure S1: Patient flow, Figure S2: Plots with number of suspicious lesions over blood levels for prostate-specific
antigen, Table S1: Quantitative parameters in patients with ADT according to the castration state, Figure S3: Plots
with whole-body total lesion PSMA over whole-body CT derived tumor volume.
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